Core Viewpoint - The collaboration between Jinan University and Zhongjing Wanshi Pharmaceutical aims to conduct clinical research on age-related degenerative diseases, leveraging traditional Chinese medicine (TCM) to address conditions such as osteoporosis, knee osteoarthritis, and Alzheimer's disease, particularly focusing on the concept of kidney deficiency [4][6]. Group 1: Event Overview - The signing ceremony for the clinical research project was held on April 29, organized by Jinan University and attended by various experts and scholars from Guangdong [2]. - Key representatives included Zhang Ronghua, Vice President of Jinan University, and Ma Yun, Deputy General Manager of Zhongjing Wanshi Pharmaceutical, who signed the cooperation agreement [6]. Group 2: Research Focus - The project will explore the pathological mechanisms and key targets of age-related degenerative diseases, emphasizing the role of kidney deficiency in these conditions [6]. - The research aims to innovate TCM applications, particularly the modern use of classic formulas like Zuo Gui Wan and You Gui Wan, in treating kidney deficiency-related diseases [4][6]. Group 3: Collaborative Goals - The collaboration seeks to integrate multidisciplinary approaches to enhance the understanding and treatment of age-related diseases through TCM [6]. - Zhongjing Wanshi Pharmaceutical emphasizes the importance of high-quality medicinal materials and aims to explore new treatment pathways that combine TCM and Western medicine [6].

Core Insights - Tong Ren Tang Guo Yao achieved a revenue of HKD 1.612 billion, representing a year-on-year growth of 5.7%, and a net profit of HKD 529 million for the reporting period [2] Group 1: Business Performance - The company launched several new products, including the NMN anti-aging series and other traditional Chinese medicine products, enhancing its product matrix [3] - Revenue from the Hong Kong market reached HKD 1.07 billion, showing a significant year-on-year increase of 16.9% despite challenges in the retail sector [6] - The company expanded its retail presence in Hong Kong, increasing the number of retail terminals to 29, a net addition of 2 stores compared to the previous year [6] Group 2: Research and Development - Tong Ren Tang Guo Yao strengthened its R&D efforts, achieving significant results in product innovation and safety studies, including the approval of Danggui Blood Supplement Granules [3][4] - The company signed a cooperation agreement with Macau University of Science and Technology to enhance research collaboration and product registration [3] Group 3: Marketing and Brand Promotion - The company actively engaged in marketing activities, including the "Tong Ren Tang Day" and the "9th Tong Ren Care Against Stroke" series, to promote its brand and cultural heritage [5][7] - Tong Ren Tang Guo Yao emphasized its commitment to public welfare as a core aspect of its brand culture, conducting health-related activities in collaboration with local institutions [7] Group 4: Future Outlook - For 2025, the company aims to focus on "adjustment and recovery, cost reduction, and efficiency enhancement," implementing strategies to optimize management, products, investments, and finances [7]